Dendritic cells and T lymphocyte interactions in patients with lymphoid malignancies

Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia

Dendritic cell vaccines for leukemia patients

Current status of immunotherapy in B cell malignancies

Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies

Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation

Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation

Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors

Vaccine strategies to treat lymphoproliferative disorders